Lymphoproliferative tumors in rheumatic diseases
https://doi.org/10.47360/1995-4484-2024-575-581
Abstract
The development of lymphoid tumors in patients with rheumatic diseases can significantly worsen the quality of life and negatively affect the prognosis. The article presents modern data on the relationship between lymphoid tumors and rheumatic diseases. Practical differential diagnosis guidelines of T cell large granular lymphocytic leukemia in patients with rheumatoid arthritis and Felty’s syndrome are given. The results of the study of pathogenesis and biological predictors of diffuse large B cell lymphoma in patients with rheumatic diseases are presented. This study of the lymphoproliferative tumor pathogenesis in patients with rheumatic diseases sheds light on the mechanisms underlying the development of sporadic lymphoproliferative tumors and autoimmune diseases, as well as on the progress in the treatment of these diseases.
About the Authors
V. R. Gorodetskiy
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Vadim R. Gorodetskiy
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
I. V. Poddubnaya
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Irina V. Poddubnaya
125993, Moscow, Barrikadnaya str., 2/1, building 1
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology ; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Evgeny L. Nasonov
115522, Moscow, Kashirskoye Highway, 34A
119991, Moscow, Trubetskaya str., 8, building 2
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
References
1. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, MartínezMaza O, Turner J, et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi: 10.1182/blood-2007-10-119974
2. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069-2077. doi: 10.1158/1055-9965.EPI-06-0300
3. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60. doi: 10.1093/jnci/djj004
4. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2001;27(4):750-756. doi: 10.1006/bcmd.2001.0442
5. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol. 2006;18(2):129-134. doi: 10.1097/01.bor.0000209423.39033.94
6. Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study. Ann Oncol. 2014;25(10):2025-2030. doi: 10.1093/annonc/mdu365
7. Kitamura W, Asada N, Tabata T, Shibata R, Nishi T, Kato Y, et al. Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. J Clin Exp Hematop. 2022;62(1):35-40. doi: 10.3960/jslrt.21010
8. Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, et al. Large granular lymphocytic leukemia – A retrospective study of 319 cases. Am J Hematol. 2021;96(7):772-780. doi: 10.1002/ajh.26183
9. Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on 229 cases. Haematologica. 2010;95(9):1534-1541. doi: 10.3324/haematol.2009.018481
10. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.
11. Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. Leuk Res. 2020;90:106299. doi: 10.1016/j.leukres.2020.106299
12. Schwaneck EC, Renner R, Junker L, Einsele H, Gadeholt O, Geissinger E, et al. Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: A comprehensive analysis of 529 patients. Arthritis Rheumatol. 2018;70(12):1914-1922. doi: 10.1002/art.40654
13. Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016;139(Pt 5):1348-1360. doi: 10.1093/brain/aww024
14. Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi: 10.1093/rheumatology/keab716
15. Quintanilla-Martinez L, Fend F. Turning up the heat on salivary gland MALT lymphoma. Blood. 2022;139(14):2094-2096. doi: 10.1182/blood.2021012624
16. Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii arkhiv. 2022;94(5):605-609 (In Russ.). doi: 10.26442/00403660.2022.05.201501
17. Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60(12):2971-2978. doi: 10.1002/1097-0142(19871215)60:12<2971::aid-cncr2820601220>3.0.co;2-o
18. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood. 1997;89(1):256-260.
19. Cheon H, Dziewulska KH, Moosic KB, Olson KC, Gru AA, Feith DJ, et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep. 2020;15(2):103-112. doi: 10.1007/s11899-020-00565-6
20. Narváez J, Domingo-Domenech E, Gómez-Vaquero C, LópezVives L, Estrada P, Aparicio M, et al. Biological agents in the management of Felty’s syndrome: A systematic review. Semin Arthritis Rheum. 2012;41(5):658-668. doi: 10.1016/j.semarthrit.2011.08.008
21. Shipley E, Héraud A, Hennette A, Vernhes JP. Efficacy of rituximab in Felty’s syndrome. Joint Bone Spine. 2008;75(5):621-622. doi: 10.1016/j.jbspin.2008.02.018
22. Wang CR, Chiu YC, Chen YC. Successful treatment of refractory neutropenia in Felty’s syndrome with rituximab. Scand J Rheumatol. 2018;47(4):340-341. doi: 10.1080/03009742.2017.1334816
23. Proc K, Madej M, Wiland P, Sebastian A. Biological treatment in Felty’s syndrome with profound neutropenia. Reumatologia. 2023;61(3):213-218. doi: 10.5114/reum/167472
24. Gorodetskiy VR, Sidorova YV, Kupryshina NA, Vasilyev VI, Probatova NA, Ryzhikova NV, et al. Analysis of a single-institution cohort of patients with Felty’s syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatol Int. 2021;41(1):147-156. doi: 10.1007/s00296-020-04757-4
25. Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20(5):245-266. doi: 10.1016/j.blre.2006.01.003
26. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362. doi: 10.1172/JCI9940
27. Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018;109(4):926-933. doi: 10.1111/cas.13525
28. Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013;27(7):1598-1600. doi: 10.1038/leu.2012.350
29. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048- 3057. doi: 10.1182/blood-2012-06-435297
30. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmä- ki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905- 1913. doi: 10.1056/NEJMoa1114885
31. Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74-81. doi: 10.1016/j.humpath.2017.12.014
32. Wegscheider C, Ferincz V, Schöls K, Maieron A. Felty’s syndrome. Front Med (Lausanne). 2023;10:1238405. doi: 10.3389/fmed.2023.1238405
33. Gorodetskiy V, Sidorova Y, Biderman B, Kupryshina N, Ryzhikova N, Sudarikov A. STAT3 mutations in “gray-zone” cases of T-cell large granular lymphocytic leukemia associated with autoimmune rheumatic diseases. Front Med (Lausanne). 2022;9:1000265. doi: 10.3389/fmed.2022.1000265
34. Armstrong RD, Fernandes L, Gibson T, Kauffmann EA. Felty’s syndrome presenting without arthritis. Br Med J (Clin Res Ed). 1983;287(6405):1620. doi: 10.1136/bmj.287.6405.1620
35. Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1(3):257-259.
36. Fitzgerald P, O’Brien AA, Daly PA. Felty’s syndrome presenting with severe extra-articular features in the absence of clinical rheumatoid arthritis. Ir Med J. 1984;77(12):397-398.
37. Rozin A, Hoffman R, Hayek T, Balbir-Gurman A. Felty’s syndrome without rheumatoid arthritis? Clin Rheumatol. 2013;32(5):701-704. doi: 10.1007/s10067-012-2157-3
38. Marchand T, Lamy T. The complex relationship between large granular lymphocyte leukemia and rheumatic disease. Expert Rev Clin Immunol. 2024;20(3):291-303. doi: 10.1080/1744666X.2023.2292758
39. Moosic KB, Ananth K, Andrade F, Feith DJ, Darrah E, Loughran TP Jr. Intersection between large granular lymphocyte leukemia and rheumatoid arthritis. Front Oncol. 2022;12:869205. doi: 10.3389/fonc.2022.869205
40. Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468(7322):447-451. doi: 10.1038/nature09518
41. Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol. 2018;30(1):72-78. doi: 10.1097/BOR.0000000000000452
42. Romero V, Fert-Bober J, Nigrovic PA, Darrah E, Haque UJ, Lee DM, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med. 2013;5(209):209ra150. doi: 10.1126/scitranslmed.3006869
43. Hohlfeld R, Schulze-Koops H. Cytotoxic T cells go awry in inclusion body myositis. Brain. 2016;139(Pt 5):1312-1314. doi: 10.1093/brain/aww053
44. Poddubnaya IV, Babicheva LG, Bariakh EA. Diffuse large B-cell lymphoma: Strokes to the epidemiological portrait. A review. Journal of Modern Oncology. 2023;25(3):342-345 (In Russ.). doi: 10.26442/18151434.2023.3.202402
45. Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005:260-266. doi: 10.1182/asheducation-2005.1.260
46. Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): A clinicopathologic study of 24 Japanese cases. Int J Surg Pathol. 2006;14(1):43-48. doi: 10.1177/106689690601400108
47. Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, et al. B-cell lymphoma associated with Sjögren’s syndrome among Japanese patients: A clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop. 2009;49(2):89-95. doi: 10.3960/jslrt.49.89
48. Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20-28. doi: 10.1111/ejh.12116
49. Gorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-x
50. Kiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer ME, Weber M, et al. Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019;186(3):448-459. doi: 10.1111/bjh.15953
51. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207. doi: 10.1200/JCO.2010.30.0368
52. Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594. doi: 10.1200/JCO.2007.15.9277
53. Ichiki A, Carreras J, Miyaoka M, Kikuti YY, Jibiki T, Tazume K, et al. Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier. J Clin Exp Hematop. 2017;57(2):54-63. doi: 10.3960/jslrt.17029
54. Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, et al. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget. 2015;6(21):18374-18388. doi: 10.18632/oncotarget.4073
55. Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688-1697. doi: 10.1038/modpathol.2017.93
56. Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217. doi: 10.1111/j.1365-2559.2008.03076.x
57. Nasonov EL. Achievements in rheumatology in the XXI century. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(2):133-140 (In Russ.). doi: 10.14412/1995-4484-2014-133-140
Review
For citations:
Gorodetskiy V.R., Poddubnaya I.V., Nasonov E.L. Lymphoproliferative tumors in rheumatic diseases. Rheumatology Science and Practice. 2024;62(6):575-581. (In Russ.) https://doi.org/10.47360/1995-4484-2024-575-581
Views:
324
Email this article 